Why Has FBR Capital Given TG Therapeutics Inc (OTC:TGTX) a $29.00 Price Target
In a recent report announced on Tuesday morning, FBR Capital analyst has today began coverage for TG Therapeutics Inc (OTC:TGTX) shares with a “Outperform” rating. The target price is exactly $29.00.
From a total of 6 analysts covering TG Therapeutics Inc (OTC:TGTX) stock, 6 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. TG Therapeutics Inc was the topic of 2 analyst reports since August 13, 2015 according to the firm StockzIntelligence Inc. Raymond James initiated shares on September 9 with “Strong Buy” rating.
The stock closed the day at $13.18 during the previous session. It is down 11.78% since April 28, 2015 and is downtrending. It has underperformed by 10.16% the S&P500.
TG Therapeutics, Inc. is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The company has a market cap of $688.01 million. As of December 31, 2014, TG had two therapies targeting hematological malignancies. It currently has negative earnings. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.” Get a free copy of the Zacks research report on TG Therapeutics Inc (TGTX)